By inhibiting IL-4 and IL-13 signaling through their shared receptor, IL-4 receptor alpha (26, 27), dupilumab effectively suppresses the type 2 inflammatory pathways underlying both AD and AR (28). This evidence concerns the gene IL13 and Alzheimer disease.